Adriamycin in the treatment of childhood solid tumors. A Southwest Oncology Group study.
Ninety-eight children with solid tumors resistant to conventional chemotherapy received adriamycin 90 mg/m2, either as a single intravenous injection or in 6 divided doses administered every 6 hours. Of the 88 evaluable children, 6 (7%) achieved a complete response and 26 (29%) achieved a partial response. Tumors which demonstrated significant response rates were: neuroblastoma (9/18), Wilms' tumor (7/13), rhabdomyosarcoma (4/11), and lymphoma (4/8). The toxicities observed with this regimen included: alopecia, leukopenia, thrombocytopenia, nausea, vomiting, stomatitis, febrile episodes, and ST-segment changes.
D000293:Adolescent; D000505:Alopecia / Q000209:etiology; D002648:Child; D002675:Child, Preschool; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D005334:Fever / Q000209:etiology; D006801:Humans; D007223:Infant; D007970:Leukopenia / Q000209:etiology; D008297:Male; D009325:Nausea / Q000209:etiology; D009369:Neoplasms / Q000188:drug therapy*; D013921:Thrombocytopenia / Q000209:etiology; D014839:Vomiting / Q000209:etiology
D004317:Doxorubicin